Register Now: IKRIS Breast Cancer Awareness Run 2022

Search results for:Bortezomib

Triplet regimen of melphalan flufenamide with dexamethasone and either daratumumab or bortezomib for RRMM

According to phase-I/IIa findings from the ANCHOR (OP-104) trial that were introduced during the second EMN (European Myeloma Network) Meeting, […]

March 18, 2021


WHAT IS BORTEZOMIB AND WHAT IT IS USED FOR? Bortezomib is a proteasome inhibitor indicated for the treatment of: Patients with […]

December 1, 2020

Cost-effectiveness of Daratumumab (Darzalex) for Adult Patients with RRMM

According to research published in Frontiers in Pharmacology, Addition of daratumumab (darzalex) to the standard care may help in order […]

April 14, 2021

Multiple Myeloma: Treatment and Medications

Being the second most common type of blood cancer, 5-6% of the world population is diagnosed with Multiple Myeloma every […]

December 8, 2020


WHAT IS CARFILZOMIB AND WHAT IT IS USED FOR? Carfilzomib is an anti-cancer drug indicated to use as a selective proteasome […]

December 2, 2020


WHAT IS DARATUMUMAB AND WHAT IT IS USED FOR: Daratumumab is an anti-cancer medication indicated for the treatment of: Multiple […]

December 2, 2020

NICE recommends a triplet therapy comprised of Kyprolis, lenalidomide and dexamethasone for MM

The NICE has specifically recommended a triplet therapy comprised of Kyprolis (carfilzomib), lenalidomide and dexamethasone in order to treat previously […]

March 23, 2021

Ikris Pharmaceutical in Brazil Health sector

We, Ikris Pharma Network are International pharmaceutical distributors from India. We supply products to all the people involved in the […]

October 20, 2021


WHAT IS POMALIDOMIDE AND WHAT IT IS USED FOR: Pomalidomide is an anti-angiogenic medication indicated for the treatment of: Relapsed […]

December 4, 2020